Main Article Content
Objective: Favipiravir is a novel, orally bioavailable, purine nucleoside analogue drug. Recent studies showed that it was related to faster viral clearance time and a significant improvement rate in chest imaging in patients with COVID-19. While the mechanism of action of Favipiravir is well characterized, there is insufficient data about its effects on haematological inflammatory parameters during COVID 19 infection.
Material and Methods: This observational study included 92 patients with COVID-19 (50 of them were female) with mild to moderate disease who taken Favipiravir in the Pandemic Center at Giresun University School of Medicine from April 2020 to October 2020. Patients with severe COVID-19 infection were excluded from the study.
Results: After the five days of Favipiravir administration, compared to before the treatment, it was observed that the neutrophil counts of the patients (before the treatment mean 5.97 109/L (5.1 - 6.84) and after treatment 4.82 109/L (4.29 - 5.35) p=0,039) and Neutrophil/lymphocyte ratio (NLR) markedly decreased (before the treatment mean 6.88 (5.33 - 8.42) and after treatment 4.67 (3.23 - 6.10) p=0,002), while the lymphocyte count increased and these alternations were statistically significant. Platelet count and MCV levels were slightly increased after the treatment also statistically significant (p<0.001, p=0.001). Although there was a significant decrease in CRP levels, no significant change was observed in other inflammatory markers (Ferritin, Sedimentation, Fibrinogen, D-Dimer, and Troponin). The overall mortality rate was 4%, with no deaths in ICU.
Conclusion: In our study; in addition to previous knowledge from recent studies; increasing in the platelet count and decreasing in CRP and MPV levels are remarkable findings. These data may guide in the follow-up of Favipiravir treatment and in determining the prognosis.
Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery, diagnostics and drug development. J Hepatol. 2021 Jan;74(1):168-84.
Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Sci Total Environ. 2020 Aug 15;730:138996.
Zhu W, Zhang Z, He S, Wong G, Banadyga L, Qiu X. Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model. Antiviral Research 2018 Feb;151:39-49.
Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother. 2020 Jul 1;75(7):2013-4.
Madelain V, Nguyen THT, Olivo A, De Lamballerie X, Guedj J, Taburet AM, et al. Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clinical pharmacokinetics. 2016 Jan;55(8): 907-23.
Favipiravir - FUJIFILM Toyama Chemical. Available from: https://adisinsight. springer. com/ drugs/800014667/ 2020 (accessed on 9 December 2020).
Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020 May;209:107512.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for covid-19: an open-label control study. Engineering (Beijing). 2020; doi:http://dx.doi. org/10.1016/j.eng.2020.03.007.
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013 Nov;100(2):446-54.
T.C. Sağlık Bakanlığı. Covid-19 bilgilendirme platformu; 2021. Available from: https://covid19.saglik.gov.tr/TR-66926/eriskin-hasta-tedavisi.html Accessed in 10.09.2020
Şimşek YS, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020 Apr 21;50(SI-1):611-619.
Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med. 2020 Apr;8(4):e24.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 March 3;doi:10.1007/s00134-020-05991-x.
Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.
Manne BK, Denorme F, Middleton EA, et al. Platelet gene expression and function in patients with COVID-19. Blood. 2020 Sep 10;136(11):1317-1329.
Salamanna F, Maglio M, Landini MP, Fini M. Platelet functions and activities as potential hematologic parameters related to Coronavirus Disease 2019 (Covid-19). Platelets. 2020 Jul 3;31(5):627-632.
Korniluk A, Koper-Lenkiewicz OM , Kamińska J, Kemona H, Dymicka-PiekarskaV. Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators Inflamm. 2019 Apr 17;2019:9213074. doi: 10.1155/2019/9213074.
Liu Y, Sun W, Guo Y, Chen L, Zhang L, Zhao S, et al. Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study. Platelets. 2020 May 18;31(4):490-496.
Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 15;19(1):18.
Vargas-Vargas M, Cortés-Rojo C. Ferritin levels and COVID-19. Rev Panam Salud Publica. 2020 Jun 1;44:e72.